NCT07648433Not yet recruiting
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in MPN Patients
Development of a Peripheral Blood Assay to Replace Bone Marrow Biopsy in Myeloproliferative Neoplasms- a Multi-center Observational Study
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
The PERIBLOOD-MPN study aims to develop and validate a minimally invasive peripheral blood test using single-cell RNA sequencing to accurately diagnose and classify myeloproliferative neoplasms, potentially reducing the need for invasive bone marrow biopsies.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 9 Jun 2026
- Start date
- Oct 2026
- Primary completion date
- Jun 2029
- Lead sponsor
- Weizmann Institute of Science
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT07648433
What you commit to
- Study type: Observational
- Planned participants: 500
- From Oct 2026 to the primary completion date, Jun 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients diagnosed with MPN receiving therapy
- Patients who have undergone a bone marrow transplant
Who the study is looking for
- Age ≥ 18 years
- Confirmed MPN diagnosis, based on the WHO criteria (Barbui 2018), which includes:
- Polycythemia Vera (PV) Criteria:
- Elevated hemoglobin (\>16.5 g/dL for men, \>16.0 g/dL for women), hematocrit (\>49% for men, \>48% for women), or increased red cell mass
- Bone marrow biopsy showing hypercellularity with trilineage growth (panmyelosis)
- Presence of JAK2 mutation (V617F or exon 12)
- Essential Thrombocythemia (ET) Criteria:
- Platelet count ≥450 ×10⁹/L
- Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage
- Not meeting WHO criteria (Alaggio et al., 2022) for other myeloid neoplasms (such as CML, PV, PMF, MDS).
- Presence of JAK2, CALR, or MPL mutation Primary Myelofibrosis (PMF) Criteria
- Megakaryocytic proliferation and atypia, with or without reticulin fibrosis, and increased marrow cellularity (for prefibrotic/early PMF) or significant reticulin/collagen fibrosis (for overt PMF)
- Not meeting criteria for other myeloid neoplasms
- Presence of JAK2, CALR, or MPL mutation, or in their absence, another clonal marker
- Patients who are referred for a bone marrow biopsy due to a suspected diagnosis of MPN
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.